• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

专利案件中的竞争政策与反垄断

Competition policy in patent cases and antitrust.

作者信息

Sobel Gerald

机构信息

Partner Kaye Scholer LLP, New York, New York 10022-3598, USA.

出版信息

Adv Genet. 2003;50:23-64; discussion 507-10. doi: 10.1016/s0065-2660(03)50003-7.

DOI:10.1016/s0065-2660(03)50003-7
PMID:14714685
Abstract

The article that follows examines the competition policy reflected in the decisions of the Court of Appeals for the Federal Circuit in its patent cases. The court's views on this subject have been manifested most plainly in decisions that have transformed the law concerning infringement under the doctrine of equivalents and claim construction. In both categories, the court narrowed patent scope by reason of its desire to protect competitors. The article argues that the court's premise in prescribing narrower claim scope reflected an incomplete view of competition policy. The court's analysis overlooked the benefits to competition provided by patents, which stimulate inventions and their development. The article traces the development of antitrust jurisprudence and demonstrates how respect for the contribution of patents to competition and skepticism of free-riding has evolved, particularly beginning in the 1970s. The article draws a parallel between the Court's reasoning about competition policy, on the one hand, and the rejected views of Justices Hugo Black and William O. Douglas and abandoned patent-antitrust jurisprudence, on the other. The Federal Circuit's decision in Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 234 F.3d 558 (Fed. Cir. 2000), on the subject of equivalents is considered in the paper. In that decision, the majority adopted a new rule that completely barred infringement under the doctrine of equivalents of any claim limitation where, in prosecution, there had been a narrowing amendment relating to patentability. In the past, prosecution estoppel foreclosing equivalents had been subject to a "flexible bar," which, in some circumstances, allowed for equivalence notwithstanding such an amendment. The article points out that because almost all patents are amended during prosecution, the effect would be to allow widespread copying of patented inventions by trivial modifications of any narrowed claim limitation. The incentive to innovate in the future would be correspondingly diminished and the expectations of past patentees would be correspondingly altered.

摘要

接下来的这篇文章审视了联邦巡回上诉法院在专利案件判决中所体现的竞争政策。该法院在这一问题上的观点,在那些改变了等同原则和权利要求解释相关法律的判决中表现得最为明显。在这两类案件中,法院出于保护竞争对手的愿望而缩小了专利范围。文章认为,法院在规定更窄权利要求范围时的前提反映了对竞争政策的不完整看法。法院的分析忽视了专利对竞争的益处,而专利能刺激发明创造及其发展。文章追溯了反垄断法理学的发展,并展示了对专利对竞争的贡献的尊重以及对搭便车行为的怀疑是如何演变的,尤其是从20世纪70年代开始。文章一方面将法院关于竞争政策的推理,与大法官雨果·布莱克和威廉·O·道格拉斯被否决的观点以及被摒弃的专利反垄断法理学进行了类比。本文还考虑了联邦巡回上诉法院在费斯托公司诉日本触媒株式会社案(Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 234 F.3d 558 (Fed. Cir. 20

相似文献

1
Competition policy in patent cases and antitrust.专利案件中的竞争政策与反垄断
Adv Genet. 2003;50:23-64; discussion 507-10. doi: 10.1016/s0065-2660(03)50003-7.
2
An analysis of the evolution of the written description requirement vis-à-vis DNA and biotechnological inventions.关于DNA和生物技术发明的书面描述要求的演变分析。
Recent Pat DNA Gene Seq. 2007;1(2):138-44. doi: 10.2174/187221507780887072.
3
The Role of Regulatory Agencies and Intellectual Property: Part II.监管机构与知识产权的作用:第二部分。
Cold Spring Harb Perspect Med. 2015 Mar 16;5(7):a020834. doi: 10.1101/cshperspect.a020834.
4
Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.针对联邦法院裁决,加强药品发明专利保护的策略。
Curr Top Med Chem. 2010;10(18):1929-36. doi: 10.2174/156802610793176701.
5
State action antitrust immunity for public hospitals: it depends on what you mean by "foreseeable".公立医院的州政府行为反垄断豁免:这取决于你对“可预见”的定义。
J Health Law. 2000 Winter;33(1):1-23.
6
Using the written description requirement to limit broad patent scope, allow competition, and encourage innovation in biotechnology.利用书面描述要求来限制宽泛的专利范围、允许竞争并鼓励生物技术领域的创新。
Health Matrix Clevel. 2004 Summer;14(2):393-435.
7
An analysis of federal circuit discrimination: the evolution of the written description requirement vis-a-vis DNA and biotechnological inventions concerns for synthetic biology.联邦巡回法院歧视分析:相对于DNA和生物技术发明而言,书面描述要求的演变涉及合成生物学。
Recent Pat DNA Gene Seq. 2011 Dec;5(3):153-65. doi: 10.2174/187221511797636284.
8
Unsettling drug patent settlements: a framework for presumptive illegality.令人不安的药品专利和解:推定非法性的框架。
Mich Law Rev. 2009 Oct;108(1):37-80.
9
Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.药品专利纠纷解决中的反垄断问题,第二部分
J Health Law. 2001 Fall;34(4):657-71.
10
The Impact of Myriad on the Future Development and Commercialization of DNA-Based Therapies and Diagnostics.Myriad对基于DNA的治疗和诊断的未来发展及商业化的影响。
Cold Spring Harb Perspect Med. 2015 Sep 3;5(12):a020925. doi: 10.1101/cshperspect.a020925.